ArticleFrontiers in pharmacology2026
Loss of the translational repressor 4E-BP1 promotes skin carcinogenesis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Skin squamous cell carcinoma (SCC) arises from dysregulated epidermal homeostasis characterized by aberrant keratinocyte proliferation and pathological angiogenesis. The eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) functions as a critical suppressor of cap-dependent translation by interacting with eIF4E, thereby constraining protein synthesis and cell growth. However, its role in SCC remains elusive. Methods: To address the role of 4E-BP1 function in SCC pathogenesis, we employed a two-stage chemical carcinogenesis model in 4E-BP1-deficient mice. Results: 4E-BP1-deficient mice exhibited a significantly increased papilloma burden compared to wild-type controls, accompanied by enhanced keratinocyte proliferation and augmented tumor vascularization. Analysis of human SCC specimens revealed elevated 4E-BP1 phosphorylation together with increased proliferative and angiogenic markers and activation of the mTOR signaling pathway, mirroring molecular features observed in 4E-BP1-deficient tumors. Discussion: Collectively, these findings establish 4E-BP1 as a tumor suppressor in skin carcinogenesis that constrains both proliferative and angiogenic processes, underscoring the contribution of dysregulated translation to SCC development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.